Lower Urinary Tract Symptoms and Benign Prostate Hyperplasia Features Among Male BRCA Mutation Carriers
| Autor: | Rachely Ozalbo, Hanan Goldberg, Liat Shavit Grievink, Jack Baniel, Roy Mano, David Margel, Sivan Tuval, Yaara Ber |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty endocrine system diseases Urology DNA Mutational Analysis Prostatic Hyperplasia 030232 urology & nephrology Endosonography 03 medical and health sciences 0302 clinical medicine Lower Urinary Tract Symptoms Prostate Lower urinary tract symptoms medicine Humans skin and connective tissue diseases Aged BRCA2 Protein medicine.diagnostic_test BRCA1 Protein business.industry BRCA mutation Magnetic resonance imaging DNA Rectal examination Middle Aged Hyperplasia Prognosis medicine.disease Magnetic Resonance Imaging Cross-Sectional Studies medicine.anatomical_structure 030220 oncology & carcinogenesis Mutation International Prostate Symptom Score business Body mass index |
| Zdroj: | Urology. 108:71-75 |
| ISSN: | 0090-4295 |
| DOI: | 10.1016/j.urology.2017.05.036 |
| Popis: | Objective To analyze lower urinary tract symptoms and benign prostate hyperplasia features among male BRCA1 and 2 carriers and an age-matched control group. Methods Male BRCA carriers and noncarriers aged 40-70 years were enrolled in our cross-sectional study. Relevant clinical data were collected, and patients filled the International Prostate Symptom Score. Patients also underwent prostate-specific antigen (PSA) blood testing, digital rectal examination, uroflowmetry, and post-void residual ultrasound examination. As part of their routine follow-up, BRCA carriers underwent prostate magnetic resonance imaging. Results Overall, 87 carriers and 30 noncarriers were enrolled. The median age, mean body mass index, and comorbidities in both groups were similar. Maximal flow (QMAX) was higher in the noncarrier group (16.9 mL/s vs 12 mL/s, P = .01). Mean prostate volume among all BRCA carriers was 38.8 cc (19.7), but BRCA1 patients had larger glands with higher mean PSA and PSA density than BRCA2 patients (41.8 cc vs 33.1 cc, P = .047, 1.84 ng/mL vs 1.07 ng/mL, P = .006, and .044 vs .032, P = .042, respectively). Multivariate analysis demonstrated age being the sole significant predictor of PSA density in BRCA2 patients. Conclusion Male carrying BRCA mutations have significantly lower QMAX than healthy men. BRCA1 patients have on average larger prostate glands and higher PSA than BRCA2 patients. Further research is required to decipher the association of lower urinary tract symptoms or benign prostate hyperplasia with BRCA carriers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect